S&P and Nasdaq futures point to mixed start for stocks after Monday's big rally.
Like a golfer who's swung, Wall Street will be concentrating on one thing Tuesday morning: follow through.
Investors looking to see if the market can build on Monday's rally may be disappointed, though, with S&P and Nasdaq futures pointing to a mixed start at best for Wall Street.
Stocks rallied Monday on a rebound in the dollar and optimism about the economy, sending the Dow industrials up 1.2 percent and the Nasdaq composite up 2.8 percent.
The gains came after two straight down weeks for stocks, and erased all of last week's declines for the Nasdaq composite and the S&P 500. (For more on Monday's markets, click on the chart).
Tuesday's big news: the government's revised reading on third-quarter economic growth, which analysts expect will be raised to a 7.6 percent growth rate from the initial reading of 7.2 percent growth, which was the strongest performance in nearly two decades.
Also on the economic calendar: a report on existing home sales for October and consumer confidence last month.
Overseas, stocks closed higher in Asia, led by gains in Japan and South Korea, and started higher in Europe.
Treasury prices edged lower, pushing the yield on the 10-year note up to 4.24 percent from 4.23 percent late Monday. Bond prices and yields move in the opposite direction.
The dollar, which rallied Monday after hitting a record low versus the euro last week, was little changed against the common European currency. The dollar edged higher against the Japanese yen.
Stocks that could be active Tuesday include Novellus Systems (NVLS: Research, Estimates), the chip equipment maker which after the close Monday boosted its forecast for fourth-quarter orders and said profits would be at the high end of its previous guidance.
Novellus shares rallied in after-hours trading.
Shares of Amylin Pharmaceuticals (AMLN: Research, Estimates) also rose in after-hours action Monday on news the experimental diabetes drug it developed with Eli Lilly and Co. (LLY: Research, Estimates) was successful in its final late-stage trial.
Like a golfer who's swung, Wall Street will be concentrating on one thing Tuesday morning: follow through.
Investors looking to see if the market can build on Monday's rally may be disappointed, though, with S&P and Nasdaq futures pointing to a mixed start at best for Wall Street.
Stocks rallied Monday on a rebound in the dollar and optimism about the economy, sending the Dow industrials up 1.2 percent and the Nasdaq composite up 2.8 percent.
The gains came after two straight down weeks for stocks, and erased all of last week's declines for the Nasdaq composite and the S&P 500. (For more on Monday's markets, click on the chart).
Tuesday's big news: the government's revised reading on third-quarter economic growth, which analysts expect will be raised to a 7.6 percent growth rate from the initial reading of 7.2 percent growth, which was the strongest performance in nearly two decades.
Also on the economic calendar: a report on existing home sales for October and consumer confidence last month.
Overseas, stocks closed higher in Asia, led by gains in Japan and South Korea, and started higher in Europe.
Treasury prices edged lower, pushing the yield on the 10-year note up to 4.24 percent from 4.23 percent late Monday. Bond prices and yields move in the opposite direction.
The dollar, which rallied Monday after hitting a record low versus the euro last week, was little changed against the common European currency. The dollar edged higher against the Japanese yen.
Stocks that could be active Tuesday include Novellus Systems (NVLS: Research, Estimates), the chip equipment maker which after the close Monday boosted its forecast for fourth-quarter orders and said profits would be at the high end of its previous guidance.
Novellus shares rallied in after-hours trading.
Shares of Amylin Pharmaceuticals (AMLN: Research, Estimates) also rose in after-hours action Monday on news the experimental diabetes drug it developed with Eli Lilly and Co. (LLY: Research, Estimates) was successful in its final late-stage trial.
3287.99
1275.09
